Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacological upregulation of PGC1α in oligodendrocytes: implications for Huntington's Disease.

Journal of Huntington's disease - 1 Jan 2013

Xiang Zhongmin, Krainc Dimitri

Abstract excerpt

The coactivator PGC1α plays a role in the transcriptional regulation of energy metabolism and its deficiency has been implicated in abnormalities of myelination and oligodendrocyte differentiation in Huntington's disease (HD). In an effort to activate PGC1α in oligodendrocytes, we found that overexpression of SIRT1 or treatment with resveratrol (RSV) and SRT1720 upregulated PGC1α expression and increased...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heterocyclic Compounds, 4 or More Rings
Share to Huntington Disease
Share to Oligodendroglia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha

Share to Resveratrol

Share to Serotonin Plasma Membrane Transport Proteins

Share to Sirtuin 1

Share to Stilbenes

Source

Identifiers

PMID: 25063433
DOI: 10.3233/JHD-130046

Genes

SIRT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacological upregulation of PGC1α in oligodendrocytes: implications for Huntington's Disease.PMID 25063433Read ↗

PGC-1α sparks the fire of neuroprotection against neurodegenerative disordersSemantic proximity Read ↗

Neuroprotective effects of <scp>PPAR</scp>‐γ agonist rosiglitazone in N171‐82Q mouse model of Huntington's diseaseSemantic proximity Read ↗

PGC-1α, a New Therapeutic Target in Huntington's Disease?Semantic proximity Read ↗

PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disordersSemantic proximity Read ↗

Dysregulation of PGC-1α-Dependent Transcriptional Programs in Neurological and Developmental Disorders: Therapeutic Challenges and OpportunitiesSemantic proximity Read ↗

The Role of PGC1α in Alzheimer’s Disease and Therapeutic InterventionsSemantic proximity Read ↗

Sirtuin 1 activator <scp>SRT</scp>2104 protects Huntington's disease miceSemantic proximity Read ↗

Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease.Semantic proximity Read ↗

Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis.Semantic proximity Read ↗

Mitochondrial Effects of PGC-1alpha Silencing in MPP+ Treated Human SH-SY5Y Neuroblastoma CellsSemantic proximity Read ↗

Glitazones, PPAR-γ and NeuroprotectionSemantic proximity Read ↗

SREBP2 delivery to striatal astrocytes normalizes transcription of cholesterol biosynthesis genes and ameliorates pathological features in Huntington’s DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.